Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H25FO5S |
Molecular Weight | 444.516 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1CC2=CC=C(S2)C3=CC=C(F)C=C3)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O
InChI
InChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
Molecular Formula | C24H25FO5S |
Molecular Weight | 444.516 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an antidiabetic drug used to improve glycemic control in people with type 2 diabetes. Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion. In extensive clinical trials, canagliflozin produced a consistent dose-dependent reduction in HbA1c of 0.77% to 1.16% when administered as monotherapy, combination with metformin, combination with metformin and a sulfonylurea, combination with metformin and pioglitazone, and in combination with insulin from a baselines of 7.8% to 8.1%, in combination with metformin, or in combination with metformin and a sulfonylurea. When added to metformin, canagliflozin 100 mg was shown to be non-inferior to both sitagliptin 100 mg and glimepiride in reductions on HbA1c at one year, whilst canagliflozin 300 mg successfully demonstrated statistical superiority over both sitagliptin and glimiperide in HbA1c reductions. Secondary efficacy endpoint of superior body weight reduction and blood pressure reduction (versus sitagliptin and glimiperide)) were observed as well. Canagliflozin produces beneficial effects on HDL cholesterol whilst increasing LDL cholesterol to produce no change in total cholesterol.
Originator
Sources: http://www.drugdevelopment-technology.com/projects/invokana-canagliflozin-for-the-treatment-of-type-2-diabetes/
Curator's Comment: Invokana (canagliflozin) was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P31639 Gene ID: 6524.0 Gene Symbol: SLC5A2 Target Organism: Homo sapiens (Human) |
4.4 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | INVOKANA Approved UseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis Launch Date2013 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1178 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26048186 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANAGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10521 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26048186 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANAGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26048186 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANAGLIFLOZIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Disc. AE: Nausea, Pneumonia... AEs leading to discontinuation/dose reduction: Nausea (0.2%) Sources: Page: 129Pneumonia (0.4%) Vulvovaginal mycotic infection (0.4%) Glomerular filtration rate decreased (0.2%) Weight decreased (0.2%) Pollakiuria (0.1%) Epidermal and dermal conditions (0.6%) |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 834 Sources: Page: 129 |
Disc. AE: Blood creatinine increased, Blood potassium increased... AEs leading to discontinuation/dose reduction: Blood creatinine increased (0.2%) Sources: Page: 129Blood potassium increased (0.2%) Glomerular filtration rate decreased (0.6%) Weight decreased (0.1%) Pollakiuria (0.2%) |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 425 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 425 Sources: Page: 9 |
Other AEs: Genital infection female, Vulvovaginal pruritus... Other AEs: Genital infection female (10.6%) Sources: Page: 9Vulvovaginal pruritus (1.6%) |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 430 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M Population Size: 430 Sources: Page: 9 |
Other AEs: Genital infection male... Other AEs: Genital infection male (4.2%) Sources: Page: 9 |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Other AEs: Urinary tract infections, Urination abnormal NOS... Other AEs: Urinary tract infections (5.9%) Sources: Page: 9Urination abnormal NOS (5.1%) Thirst (2.8%) Constipation (1.8%) Nausea (2.1%) |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 425 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 425 Sources: Page: 9 |
Other AEs: Genital infection female, Vulvovaginal pruritus... Other AEs: Genital infection female (11.6%) Sources: Page: 9Vulvovaginal pruritus (3.2%) |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 842 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 842 Sources: Page: 9 |
Disc. AE: Mycoplasma genitalium infection... AEs leading to discontinuation/dose reduction: Mycoplasma genitalium infection (0.7%) Sources: Page: 9 |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 430 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M Population Size: 430 Sources: Page: 9 |
Other AEs: Genital infection male... Other AEs: Genital infection male (3.8%) Sources: Page: 9 |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 825 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M Population Size: 825 Sources: Page: 9 |
Disc. AE: Mycoplasma genitalium infection... AEs leading to discontinuation/dose reduction: Mycoplasma genitalium infection (0.5%) Sources: Page: 9 |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 1667 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 1667 Sources: Page: 9 |
Disc. AE: Hypersensitivity... Other AEs: Limb amputation... AEs leading to discontinuation/dose reduction: Hypersensitivity (2 patients) Other AEs:Limb amputation Sources: Page: 9 |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Other AEs: Urinary tract infections, Urination abnormal NOS... Other AEs: Urinary tract infections (4.4%) Sources: Page: 9Urination abnormal NOS (4.6%) Thirst (2.4%) Constipation (2.4%) Nausea (2.3%) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 56 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 56 Sources: |
Other AEs: Pollakiuria... Other AEs: Pollakiuria (below serious, 3 patients) Sources: |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Other AEs: Anaemia vitamin B12 deficiency, Disseminated intravascular coagulation... Other AEs: Anaemia vitamin B12 deficiency (serious, 1 patient) Sources: Disseminated intravascular coagulation (serious, 1 patient) Anaemia hypochromic (serious, 1 patient) Anaemia iron deficiency (serious, 2 patients) Lymphadenopathy (serious, 1 patient) Pancytopenia (serious, 1 patient) Acute coronary syndrome (serious, 12 patients) Angina pectoris (serious, 21 patient) Arrhythmia (serious, 2 patients) Arteriosclerosis coronary artery (serious, 4 patients) Atrioventricular block first degree (serious, 1 patient) Cardiac tamponade (serious, 1 patient) Cardio-respiratory arrest (serious, 4 patients) Cor pulmonale (serious, 1 patient) Coronary artery occlusion (serious, 3 patients) Hypertensive heart disease (serious, 2 patients) Myocarditis (serious, 1 patient) Right ventricular failure (serious, 1 patient) Ventricular extrasystoles (serious, 2 patients) Vertigo positional (serious, 1 patient) Goitre (serious, 2 patients) Hypothyroidism (serious, 1 patient) Inappropriate antidiuretic hormone secretion (serious, 1 patient) Thyroid mass (serious, 2 patients) Diabetic retinopathy (serious, 7 patients) Maculopathy (serious, 2 patients) Ischaemic optic neuropathy (serious, 1 patient) Retinal detachment (serious, 3 patients) Uveitis (serious, 1 patient) Vitreous adhesions (serious, 1 patient) Vitreous haemorrhage (serious, 4 patients) Abdominal fat apron (serious, 1 patient) Abdominal incarcerated hernia (serious, 1 patient) Abdominal pain lower (serious, 1 patient) Anal haemorrhage (serious, 1 patient) Colitis (serious, 1 patient) Diarrhoea (serious, 3 patients) Diverticulum (serious, 1 patient) Diverticulum intestinal haemorrhagic (serious, 1 patient) Duodenal ulcer (serious, 2 patients) Duodenitis (serious, 2 patients) Faeces discoloured (serious, 1 patient) Food poisoning (serious, 1 patient) Gastric ulcer (serious, 2 patients) Gastritis (serious, 3 patients) Hernia inguinal (serious, 4 patients) Intestinal obstruction (serious, 7 patients) Intestinal perforation (serious, 1 patient) Leukoplakia oral (serious, 1 patient) Lower gastrointestinal haemorrhage (serious, 1 patient) Melaena (serious, 1 patient) Obstructive pancreatitis (serious, 1 patient) Pancreatitis (serious, 4 patients) Rectal polyp (serious, 1 patient) Small intestinal haemorrhage (serious, 1 patient) Umbilical hernia (serious, 1 patient) Upper gastrointestinal haemorrhage (serious, 4 patients) Cardiac death (serious, 3 patients) Complication associated with device (serious, 1 patient) Critical illness (serious, 1 patient) Death (serious, 7 patients) Gait disturbance (serious, 1 patient) General physical health deterioration (serious, 1 patient) Hernia incarcerated (serious, 1 patient) Non-cardiac chest pain (serious, 8 patients) Pyrexia (serious, 2 patients) Systemic inflammatory response syndrome (serious, 1 patient) Cholangitis acute (serious, 1 patient) Cholangitis sclerosing (serious, 1 patient) Cholecystitis acute (serious, 5 patients) Cholecystitis chronic (serious, 3 patients) Cholelithiasis (serious, 5 patients) Hepatic function abnormal (serious, 1 patient) Abdominal sepsis (serious, 1 patient) Abscess limb (serious, 3 patients) Acute hepatitis B (serious, 1 patient) Arthritis bacterial (serious, 2 patients) Atypical pneumonia (serious, 1 patient) Campylobacter colitis (serious, 1 patient) Clostridium difficile colitis (serious, 2 patients) Clostridium difficile infection (serious, 1 patient) Cystitis (serious, 2 patients) Device related infection (serious, 1 patient) Diabetic gangrene (serious, 5 patients) Diverticulitis (serious, 4 patients) Ear infection (serious, 1 patient) Empyema (serious, 1 patient) Enterobacter infection (serious, 1 patient) Gas gangrene (serious, 1 patient) Gastroenteritis bacterial (serious, 1 patient) Graft infection (serious, 1 patient) Haemophilus infection (serious, 1 patient) Influenza (serious, 3 patients) Laryngitis (serious, 1 patient) Fasciitis necrotising (serious, 2 patients) Onychomycosis (serious, 1 patient) Osteomyelitis acute (serious, 2 patients) Chronic osteomyelitis (serious, 1 patient) Perineal abscess (serious, 1 patient) Pharyngeal abscess (serious, 1 patient) Pneumococcal pneumonia (serious, 1 patient) Pneumonia streptococcal (serious, 1 patient) Pulmonary sepsis (serious, 1 patient) Pyelonephritis acute (serious, 4 patients) Rectal abscess (serious, 1 patient) Respiratory tract infection viral (serious, 1 patient) Scrub typhus (serious, 1 patient) Soft tissue infection (serious, 1 patient) Infection staphylococcal (serious, 1 patient) Subcutaneous abscess (serious, 1 patient) Tonsillitis (serious, 1 patient) Urinary tract infection (serious, 25 patients) Urinary tract infection fungal (serious, 1 patient) Wound infection (serious, 6 patients) Concussion (serious, 1 patient) Facial bones fracture (serious, 1 patient) Femoral neck fracture (serious, 4 patients) Femur fracture (serious, 5 patients) Fibula fracture (serious, 2 patients) Foot fracture (serious, 1 patient) Fracture displacement (serious, 1 patient) Humerus fracture (serious, 4 patients) Joint dislocation (serious, 1 patient) Ligament rupture (serious, 1 patient) Limb injury (serious, 1 patient) Meniscus injury (serious, 1 patient) Muscle strain (serious, 1 patient) Post procedural haemorrhage (serious, 1 patient) Postoperative thrombosis (serious, 1 patient) Postoperative wound complication (serious, 1 patient) Pubis fracture (serious, 2 patients) Road traffic accident (serious, 1 patient) Soft tissue injury (serious, 1 patient) Sternal fracture (serious, 1 patient) Stress fracture (serious, 1 patient) Haemorrhage subdural (serious, 1 patient) Thermal burn (serious, 2 patients) Thoracic vertebral fracture (serious, 1 patient) Tibia fracture (serious, 2 patients) Ulna fracture (serious, 2 patients) Vascular graft occlusion (serious, 2 patients) Aspiration bronchial (serious, 1 patient) Biopsy kidney (serious, 1 patient) Blood creatine phosphokinase increased (serious, 2 patients) Blood urea increased (serious, 1 patient) Glomerular filtration rate decreased (serious, 5 patients) Cachexia (serious, 1 patient) Diabetic ketoacidosis (serious, 9 patients) Fluid retention (serious, 1 patient) Hypoglycaemia (serious, 17 patients) Hypophagia (serious, 1 patient) Lactic acidosis (serious, 1 patient) Obesity (serious, 2 patients) Back pain (serious, 2 patients) Cervical spinal stenosis (serious, 1 patient) Haemarthrosis (serious, 1 patient) Intervertebral disc degeneration (serious, 1 patient) Muscular weakness (serious, 2 patients) Musculoskeletal chest pain (serious, 2 patients) Osteitis (serious, 1 patient) Osteochondrosis (serious, 1 patient) Spinal column stenosis (serious, 1 patient) Osteoarthritis spinal (serious, 4 patients) Symphysiolysis (serious, 1 patient) Acute leukaemia (serious, 1 patient) Adenocarcinoma of colon (serious, 2 patients) B-cell lymphoma (serious, 1 patient) Basal cell carcinoma (serious, 2 patients) Bladder cancer (serious, 5 patients) Brain cancer metastatic (serious, 1 patient) Brain neoplasm (serious, 1 patient) Breast cancer (serious, 3 patients) Cholangiocarcinoma (serious, 2 patients) Colon adenoma (serious, 1 patient) Colon cancer (serious, 6 patients) Endometrial adenocarcinoma (serious, 1 patient) Gastric cancer (serious, 3 patients) Gastric neoplasm (serious, 1 patient) Hepatic neoplasm (serious, 1 patient) Invasive breast carcinoma (serious, 1 patient) Invasive ductal breast carcinoma (serious, 2 patients) Invasive lobular breast carcinoma (serious, 1 patient) Large intestine benign neoplasm (serious, 1 patient) Laryngeal cancer (serious, 1 patient) Lung cancer metastatic (serious, 2 patients) Lung neoplasm (serious, 2 patients) Malignant meningioma (serious, 1 patient) Metastases to bone (serious, 2 patients) Metastatic renal cell carcinoma (serious, 1 patient) Myelodysplastic syndrome (serious, 1 patient) Oesophageal adenocarcinoma (serious, 1 patient) Ovarian endometrioid carcinoma (serious, 1 patient) Pancreatic carcinoma metastatic (serious, 1 patient) Pancreatic neoplasm (serious, 1 patient) Prostate cancer (serious, 8 patients) Prostatic adenoma (serious, 2 patients) Rectal adenoma (serious, 1 patient) Renal oncocytoma (serious, 1 patient) Salivary gland neoplasm (serious, 1 patient) Squamous cell carcinoma of skin (serious, 2 patients) Transitional cell cancer of the renal pelvis and ureter (serious, 2 patients) Transitional cell carcinoma (serious, 3 patients) Brain injury (serious, 1 patient) Brain oedema (serious, 2 patients) Carpal tunnel syndrome (serious, 2 patients) Cauda equina syndrome (serious, 1 patient) Cerebellar haemorrhage (serious, 1 patient) Cerebellar stroke (serious, 1 patient) Chronic inflammatory demyelinating polyradiculoneuropathy (serious, 1 patient) Clonus (serious, 1 patient) Dementia (serious, 2 patients) Diabetic autonomic neuropathy (serious, 1 patient) Diabetic hyperosmolar coma (serious, 1 patient) Embolic cerebral infarction (serious, 1 patient) Encephalopathy (serious, 2 patients) Facial paralysis (serious, 1 patient) Generalised tonic-clonic seizure (serious, 1 patient) Haemorrhagic transformation stroke (serious, 1 patient) Intracranial mass (serious, 1 patient) Ischaemic neuropathy (serious, 1 patient) Lumbosacral radiculopathy (serious, 1 patient) Metabolic encephalopathy (serious, 1 patient) Myelopathy (serious, 1 patient) Paraparesis (serious, 1 patient) Parkinson's disease (serious, 1 patient) Peripheral sensorimotor neuropathy (serious, 1 patient) Polyneuropathy (serious, 1 patient) Seizure (serious, 2 patients) Spinal cord compression (serious, 1 patient) Syncope (serious, 4 patients) Tension headache (serious, 2 patients) Transient ischaemic attack (serious, 10 patients) Vasculitis cerebral (serious, 1 patient) VIth nerve paralysis (serious, 1 patient) Abortion spontaneous (serious, 1 patient) Retained products of conception (serious, 1 patient) Confusional state (serious, 2 patients) Substance-induced psychotic disorder (serious, 1 patient) Suicide attempt (serious, 1 patient) Anuria (serious, 1 patient) Bladder cyst (serious, 1 patient) Calculus urinary (serious, 1 patient) Diabetic nephropathy (serious, 12 patients) Nephrolithiasis (serious, 1 patient) Nephrotic syndrome (serious, 2 patients) Bladder neurogenic (serious, 1 patient) Colic renal (serious, 1 patient) Renal impairment (serious, 10 patients) Renal injury (serious, 1 patient) Renal tubular necrosis (serious, 1 patient) Stress urinary incontinence (serious, 1 patient) Ureterolithiasis (serious, 1 patient) Urinary retention (serious, 2 patients) Adenomyosis (serious, 1 patient) Cervix disorder (serious, 1 patient) Cystocele (serious, 1 patient) Ovarian cyst (serious, 1 patient) Rectocele (serious, 1 patient) Uterine prolapse (serious, 1 patient) Uterovaginal prolapse (serious, 1 patient) Prolapse vaginal (serious, 1 patient) Asthma (serious, 2 patients) Bronchiectasis (serious, 1 patient) Bronchitis chronic (serious, 1 patient) Bronchospasm (serious, 1 patient) Chronic respiratory failure (serious, 1 patient) Cough (serious, 2 patients) Dyspnoea at rest (serious, 1 patient) Hypoxia (serious, 1 patient) Laryngeal haematoma (serious, 1 patient) Pleuritic pain (serious, 1 patient) Pulmonary embolism (serious, 7 patients) Pulmonary fibrosis (serious, 4 patients) Pulmonary infarction (serious, 1 patient) Angioedema (serious, 2 patients) Diabetic foot (serious, 15 patients) Diabetic ulcer (serious, 1 patient) Drug eruption (serious, 1 patient) Erythema (serious, 1 patient) Neuropathic ulcer (serious, 1 patient) Generalised rash (serious, 1 patient) Skin ulcer (serious, 18 patients) Accelerated hypertension (serious, 1 patient) Aortic dissection (serious, 1 patient) Arterial disorder (serious, 1 patient) Arterial insufficiency (serious, 1 patient) Circulatory collapse (serious, 1 patient) Extremity necrosis (serious, 9 patients) Haematoma (serious, 2 patients) Hypotension (serious, 4 patients) Claudication intermittent (serious, 1 patient) Leriche syndrome (serious, 1 patient) Peripheral artery occlusion (serious, 2 patients) Disorder peripheral vascular (serious, 5 patients) Peripheral venous disease (serious, 1 patient) Haemorrhagic shock (serious, 1 patient) Subclavian artery stenosis (serious, 1 patient) Thrombosis (serious, 1 patient) Vascular occlusion (serious, 1 patient) Diabetic retinopathy (below serious, 65 patients) Nausea (below serious, 54 patients) Onychomycosis (below serious, 45 patients) Urinary tract infection (below serious, 202 patients) Pain in extremity (below serious, 56 patients) Headache (below serious, 69 patients) Skin ulcer (below serious, 85 patients) Hypotension (below serious, 57 patients) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 13 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 13 Sources: |
Other AEs: Pneumonia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pollakiuria | 0.1% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Glomerular filtration rate decreased | 0.2% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Nausea | 0.2% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Weight decreased | 0.2% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Pneumonia | 0.4% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Vulvovaginal mycotic infection | 0.4% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Epidermal and dermal conditions | 0.6% Disc. AE |
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 833 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 833 Sources: Page: 129 |
Weight decreased | 0.1% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 834 Sources: Page: 129 |
Blood creatinine increased | 0.2% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 834 Sources: Page: 129 |
Blood potassium increased | 0.2% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 834 Sources: Page: 129 |
Pollakiuria | 0.2% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 834 Sources: Page: 129 |
Glomerular filtration rate decreased | 0.6% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 129 |
unhealthy, adult n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 834 Sources: Page: 129 |
Vulvovaginal pruritus | 1.6% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 425 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 425 Sources: Page: 9 |
Genital infection female | 10.6% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 425 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 425 Sources: Page: 9 |
Genital infection male | 4.2% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 430 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M Population Size: 430 Sources: Page: 9 |
Constipation | 1.8% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Nausea | 2.1% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Thirst | 2.8% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Urination abnormal NOS | 5.1% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Urinary tract infections | 5.9% | 100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Genital infection female | 11.6% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 425 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 425 Sources: Page: 9 |
Vulvovaginal pruritus | 3.2% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 425 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 425 Sources: Page: 9 |
Mycoplasma genitalium infection | 0.7% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 842 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: F Population Size: 842 Sources: Page: 9 |
Genital infection male | 3.8% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 430 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M Population Size: 430 Sources: Page: 9 |
Mycoplasma genitalium infection | 0.5% Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 825 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M Population Size: 825 Sources: Page: 9 |
Limb amputation | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 1667 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 1667 Sources: Page: 9 |
|
Hypersensitivity | 2 patients Disc. AE |
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 1667 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 1667 Sources: Page: 9 |
Nausea | 2.3% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Constipation | 2.4% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Thirst | 2.4% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Urinary tract infections | 4.4% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Urination abnormal NOS | 4.6% | 300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: Page: 9 |
unhealthy, mean 56 years n = 834 Health Status: unhealthy Condition: type 2 diabetes Age Group: mean 56 years Sex: M+F Population Size: 834 Sources: Page: 9 |
Pollakiuria | below serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 56 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 56 Sources: |
Urinary tract infection | below serious, 202 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Onychomycosis | below serious, 45 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Nausea | below serious, 54 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pain in extremity | below serious, 56 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypotension | below serious, 57 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic retinopathy | below serious, 65 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Headache | below serious, 69 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Skin ulcer | below serious, 85 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Abdominal fat apron | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Abdominal incarcerated hernia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Abdominal pain lower | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Abdominal sepsis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Abortion spontaneous | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Accelerated hypertension | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Acute hepatitis B | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Acute leukaemia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Adenomyosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Anaemia hypochromic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Anaemia vitamin B12 deficiency | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Anal haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Anuria | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Aortic dissection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Arterial disorder | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Arterial insufficiency | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Aspiration bronchial | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Atrioventricular block first degree | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Atypical pneumonia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
B-cell lymphoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Biopsy kidney | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Bladder cyst | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Bladder neurogenic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Blood urea increased | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Brain cancer metastatic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Brain injury | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Brain neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Bronchiectasis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Bronchitis chronic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Bronchospasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cachexia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Calculus urinary | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Campylobacter colitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cardiac tamponade | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cauda equina syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cerebellar haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cerebellar stroke | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cervical spinal stenosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cervix disorder | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cholangitis acute | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cholangitis sclerosing | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Chronic inflammatory demyelinating polyradiculoneuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Chronic osteomyelitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Chronic respiratory failure | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Circulatory collapse | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Claudication intermittent | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Clonus | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Clostridium difficile infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Colic renal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Colitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Colon adenoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Complication associated with device | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Concussion | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cor pulmonale | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Critical illness | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cystocele | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Device related infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic autonomic neuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic hyperosmolar coma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic ulcer | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Disseminated intravascular coagulation | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diverticulum intestinal haemorrhagic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diverticulum | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Drug eruption | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Dyspnoea at rest | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ear infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Embolic cerebral infarction | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Empyema | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Endometrial adenocarcinoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Enterobacter infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Erythema | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Facial bones fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Facial paralysis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Faeces discoloured | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Fluid retention | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Food poisoning | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Foot fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Fracture displacement | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gait disturbance | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gas gangrene | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gastric neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gastroenteritis bacterial | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
General physical health deterioration | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Generalised rash | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Generalised tonic-clonic seizure | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Graft infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Haemarthrosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Haemophilus infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Haemorrhage subdural | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Haemorrhagic shock | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Haemorrhagic transformation stroke | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hepatic function abnormal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hepatic neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hernia incarcerated | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypophagia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypothyroidism | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypoxia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Inappropriate antidiuretic hormone secretion | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Infection staphylococcal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Intervertebral disc degeneration | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Intestinal perforation | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Intracranial mass | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Invasive breast carcinoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Invasive lobular breast carcinoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ischaemic neuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ischaemic optic neuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Joint dislocation | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Lactic acidosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Large intestine benign neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Laryngeal cancer | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Laryngeal haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Laryngitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Leriche syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Leukoplakia oral | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ligament rupture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Limb injury | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Lower gastrointestinal haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Lumbosacral radiculopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Lymphadenopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Malignant meningioma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Melaena | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Meniscus injury | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Metabolic encephalopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Metastatic renal cell carcinoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Muscle strain | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Myelodysplastic syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Myelopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Myocarditis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Nephrolithiasis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Neuropathic ulcer | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Obstructive pancreatitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Oesophageal adenocarcinoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Onychomycosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Osteitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Osteochondrosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ovarian cyst | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ovarian endometrioid carcinoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pancreatic carcinoma metastatic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pancreatic neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pancytopenia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Paraparesis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Parkinson's disease | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Perineal abscess | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Peripheral sensorimotor neuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Peripheral venous disease | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pharyngeal abscess | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pleuritic pain | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pneumococcal pneumonia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pneumonia streptococcal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Polyneuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Post procedural haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Postoperative thrombosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Postoperative wound complication | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Prolapse vaginal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pulmonary infarction | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pulmonary sepsis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Rectal abscess | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Rectal adenoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Rectal polyp | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Rectocele | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Renal injury | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Renal oncocytoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Renal tubular necrosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Respiratory tract infection viral | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Retained products of conception | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Right ventricular failure | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Road traffic accident | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Salivary gland neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Scrub typhus | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Small intestinal haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Soft tissue infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Soft tissue injury | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Spinal column stenosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Spinal cord compression | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Sternal fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Stress fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Stress urinary incontinence | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Subclavian artery stenosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Subcutaneous abscess | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Substance-induced psychotic disorder | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Suicide attempt | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Symphysiolysis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Systemic inflammatory response syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Thoracic vertebral fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Thrombosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Tonsillitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Umbilical hernia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ureterolithiasis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Urinary tract infection fungal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Uterine prolapse | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Uterovaginal prolapse | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Uveitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
VIth nerve paralysis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Vascular occlusion | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Vasculitis cerebral | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Vertigo positional | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Vitreous adhesions | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Renal impairment | serious, 10 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Transient ischaemic attack | serious, 10 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Acute coronary syndrome | serious, 12 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic nephropathy | serious, 12 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic foot | serious, 15 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypoglycaemia | serious, 17 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Skin ulcer | serious, 18 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Adenocarcinoma of colon | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Anaemia iron deficiency | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Angioedema | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Arrhythmia | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Arthritis bacterial | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Asthma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Back pain | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Basal cell carcinoma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Blood creatine phosphokinase increased | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Brain oedema | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Carpal tunnel syndrome | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cholangiocarcinoma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Clostridium difficile colitis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Confusional state | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cough | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cystitis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Dementia | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Duodenal ulcer | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Duodenitis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Encephalopathy | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Fasciitis necrotising | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Fibula fracture | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gastric ulcer | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Goitre | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Haematoma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypertensive heart disease | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Invasive ductal breast carcinoma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Lung cancer metastatic | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Lung neoplasm | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Maculopathy | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Metastases to bone | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Muscular weakness | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Musculoskeletal chest pain | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Nephrotic syndrome | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Obesity | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Osteomyelitis acute | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Peripheral artery occlusion | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Prostatic adenoma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pubis fracture | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pyrexia | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Seizure | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Squamous cell carcinoma of skin | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Tension headache | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Thermal burn | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Thyroid mass | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Tibia fracture | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Transitional cell cancer of the renal pelvis and ureter | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ulna fracture | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Urinary retention | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Vascular graft occlusion | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Ventricular extrasystoles | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Angina pectoris | serious, 21 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Urinary tract infection | serious, 25 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Abscess limb | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Breast cancer | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cardiac death | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cholecystitis chronic | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Coronary artery occlusion | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diarrhoea | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gastric cancer | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Gastritis | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Influenza | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Retinal detachment | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Transitional cell carcinoma | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Arteriosclerosis coronary artery | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cardio-respiratory arrest | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diverticulitis | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Femoral neck fracture | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hernia inguinal | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Humerus fracture | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Hypotension | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Osteoarthritis spinal | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pancreatitis | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pulmonary fibrosis | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pyelonephritis acute | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Syncope | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Upper gastrointestinal haemorrhage | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Vitreous haemorrhage | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Bladder cancer | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cholecystitis acute | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Cholelithiasis | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic gangrene | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Disorder peripheral vascular | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Femur fracture | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Glomerular filtration rate decreased | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Colon cancer | serious, 6 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Wound infection | serious, 6 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Death | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic retinopathy | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Intestinal obstruction | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pulmonary embolism | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Non-cardiac chest pain | serious, 8 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Prostate cancer | serious, 8 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Diabetic ketoacidosis | serious, 9 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Extremity necrosis | serious, 9 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 2200 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 2200 Sources: |
Pneumonia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 13 Health Status: unhealthy Condition: Type 2 Diabetes Mellitus Population Size: 13 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=70 Page: 70.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=70 Page: 70,72 |
yes | yes (co-administration study) Comment: efflux was inhibited up to 95% by verapamil (P-gp inhibitor); with cyclosporine increased the AUC of canagliflozin by 23% with no change in Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=70 Page: 70,72 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=68 Page: 68,73,88 |
yes | yes (co-administration study) Comment: probenecid increased the plasma canagliflozin Cmax and AUCtau by 13% and 21%, respectively; mean plasma Cmax and AUCinf values for canagliflozin were approximately 30% and 52% lower, respectively, when administered with rifampin (inducer) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=68 Page: 68,73,88 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=68 Page: 68,73,88 |
yes | yes (pharmacogenomic study) Comment: probenecid increased the plasma canagliflozin Cmax and AUCtau by 13% and 21%, respectively; mean plasma Cmax and AUCinf values for canagliflozin were approximately 30% and 52% lower, respectively, when administered with rifampin (inducer); carriers of the UGT1A9*3 allele exhibit higher plasma canagliflozin trough concentrations on average Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf#page=68 Page: 68,73,88 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000PharmR.pdf#page=75 Page: 75.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. | 2010 Sep 9 |
|
Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. | 2011 Jan 13 |
|
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. | 2012 |
|
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. | 2013 Jun |
|
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. | 2014 Dec 5 |
Sample Use Guides
The recommended starting dose is 100 mg once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily in patients tolerating; 100 mg once daily who have an eGFR of 60 mL/min/1.73 m^2 or greater and require additional glycemic control
Route of Administration:
Oral
For sodium-dependent glucose uptake in Chinese Hamster Ovary (CHO) cells expressing SGLT1 and SGLT2 co-transporters parental CHO-K (CHOK) cells expressing human or mouse SGLT1 and SGLT2 were seeded into 96-well plates, washed one time with 0.15 ml assay buffer at 37°C. After the assay buffer was removed 0.3–300 nM canagliflozin was added, followed by 10 minutes of incubation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:23:57 GMT 2023
by
admin
on
Fri Dec 15 16:23:57 GMT 2023
|
Record UNII |
6S49DGR869
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000187059
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
||
|
WHO-ATC |
A10BD16
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
||
|
NCI_THESAURUS |
C98083
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
||
|
WHO-VATC |
QA10BX11
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
||
|
WHO-ATC |
A10BX11
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
||
|
WHO-ATC |
A10BK02
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB33463
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
24812758
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
C91019
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
N0000187058
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | Sodium-Glucose Transporter 2 Inhibitors [MoA] | ||
|
73272
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
842133-18-0
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
6S49DGR869
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
100000127420
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
DTXSID601004469
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
DB08907
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
6S49DGR869
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
m11716
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | |||
|
1546031
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
9225
Created by
admin on Fri Dec 15 16:23:57 GMT 2023 , Edited by admin on Fri Dec 15 16:23:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SOLVATE->ANHYDROUS | |||
|
EXCRETED UNCHANGED |
URINE
|
||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BINDER->LIGAND |
Protein binding is independent of canagliflozin plasma concentrations.
BINDING
|
||
|
LABELED -> NON-LABELED |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
FECAL; PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Tmax | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
SINGLE INTRAVENOUS ADMINISTRATION |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||